Routine Health Data Outperforming Trial Data for AI Training — FDA Lag
OVERVIEWResearch indicates that routine healthcare data (EHR data, claims data, real-world evidence) often outperforms clinical trial data for training AI systems. However, FDA regulatory frameworks still prioritize trial data, creating a gap between optimal AI development practices and regulatory guidance. Why Routine Data Outperforms Trial Data: 1. Scale: Routine data includes millions of patients vs. thousands in trials 2. Diversity: Real-world data includes broader patient populations 3. Outcomes: Routine data captures long-term outcomes; trials capture short-term results 4. Relevance: AI trained on routine data performs better on routine clinical cases FDA Regulatory Lag: FDA guidance emphasizes clinical trial data for medical device validation, reflecting traditional device development practices. However, AI development benefits from routine data that FDA doesn't yet recognize as equivalent evidence. 2027 Regulatory Shift: FDA is expected to revise AI device guidance in 2027 to explicitly recognize routine health data as valid training and validation data. This would align regulatory frameworks with optimal AI development practices. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.